Category: Oncology
-
Sensei Bio stock skyrockets on acquisition and $200m financing
Sensei stock surges after acquiring Faeth Therapeutics and securing $200 million private placement to advance cancer pipeline.
-
Evogene and Australian Uni partner to tackle chemotherapy resistance in lung cancer
AI-driven collaboration between the Israeli company and Queensland University of Technology targets cellular pathways to overcome treatment hurdles in non-small cell lung cancer.
-
2025 in Review: Global biotech and funding trends
Deepali Suri, President of ICON Biotech, discusses Asia’s clinical trial boom, funding shifts, and why neurology and cardiology are surpassing oncology.
-
CAR T enters a new era of in vivo reprogramming of T cells
Vyriad’s Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.
-
Arkin Bio Ventures III: $100 million fund for transformative therapies
Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.
-
VCU researchers win $1.8 million US DoD grant for cancer therapy
The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.
-
FoRx secures $50 million to advance PARG inhibitor
Swiss biotech raises Series A financing to advance PARG inhibitor FORX-428, with initial clinical data expected in 2026.
-
CTMC maps out plans to democratize cell therapy
CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide, starting with Brazil.
-
SABCS25: Agendia’s genomic testing guides breast cancer care
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.
-
Telix bolsters data for PET imaging agent, helps optimize treatment
ZIRCON-X study shows Telix Pharmaceuticals’ Zircaix changes help reduce unnecessary invasive procedures in patients with indeterminate renal masses.
-
UK launches nuclear-driven push into precision cancer medicine
Recycled nuclear materials to fuel next-generation targeted alpha treatments in a major UK initiative.
-
Adagene & Third Arc Bio forge $845 million T-cell engager pact
Adagene licenses its SAFEbody tech to Third Arc Bio for two masked CD3 T cell engagers, netting $5million upfront, and upto $840 million in milestone payments.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.